Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,225
datasets available to search
ShareScore release 0.9.0
Dataset results
5,225 results for “moderation”
Effects of combined training or moderate intensity continuous training during a 3‑week multidisciplinary body weight reduction program on cardiorespiratory fitness, body composition, and substrate oxidation rate in adolescents with obesity
<p>This study aimed to investigate the effects of combined training (COMB, a combination of moderate intensity continuous training-MICT and high-intensity interval training-HIIT) vs. continuous MICT administered during a 3-week in-hospital body weight reduction program (BWRP) on body composition, physical capacities, and substrate oxidation in adolescents with obesity. The 3-week in-hospital BWRP entailed moderate energy restriction, nutritional education, psychological counseling, and two different protocols of physical exercise. Twenty-one male adolescents with obesity (mean age: 16.1 ± 1.5 years; mean body mass index [BMI] 37.8 ± 4.5 kg m2) participated in this randomized control trial study (n:10 for COMB, n:11 MICT), attending ~ 30 training sessions. The COMB group performed 3 repetitions of 2 min at 95% of peak oxygen uptake (V′O2 peak) (e.g., HIIT ≤ 20%), followed by 30 min at 60% of V′O2 peak (e.g., MICT ≥ 80%). Body composition, V′O2 peak, basal metabolic rate (BMR), energy expenditure, and substrate oxidation rate were measured during the first week (W0) and at the end of three weeks of training (W3). The two training programs were equivalent in caloric expenditure. At W3, body mass (BM) and fat mass (FM) decreased significantly in both groups, although the decrease in BM was significantly greater in the MICT group than in the COMB group (BM: − 5.0 ± 1.2 vs. − 8.4 ± 1.5, P < 0.05; FM: − 4.3 ± 3.0 vs. − 4.2 ± 1.9 kg, P < 0.05). V′O2 peak increased only in the COMB by a mean of 0.28 ± 0.22 L min−1 (P < 0.05). The maximal fat oxidation rate (MFO) increased only in the COMB group by 0.04 ± 0.03 g min−1 (P < 0.05). COMB training represents a viable alternative to MICT for improving anthropometric characteristics, physical capacities, and MFO in adolescents with obesity during a 3-week in-hospital BWRP.</p>
ScreenFlow: Strategy for Finding Cases of Moderate-to-Severe COPD
ClinicalTrials.gov study NCT02753556. IPD Sharing: NO. Countries: 0. Publications: 0.
Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis
ClinicalTrials.gov study NCT03059693. IPD Sharing: YES. Countries: 0. Publications: 0.
A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequat
ClinicalTrials.gov study NCT01878318. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension
ClinicalTrials.gov study NCT02176499. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
ClinicalTrials.gov study NCT02568150. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
ClinicalTrials.gov study NCT05056779. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Feasibility of Multi-modal Physical Therapy in Latino Older Adults With Moderate Knee Osteoarthritis
ClinicalTrials.gov study NCT04219423. IPD Sharing: YES. Countries: 0. Publications: 0.
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
ClinicalTrials.gov study NCT07116889. IPD Sharing: NO. Countries: 3. Publications: 0.
Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19
ClinicalTrials.gov study NCT04801056. IPD Sharing: NO. Countries: 0. Publications: 0.
Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia
ClinicalTrials.gov study NCT03626298. IPD Sharing: NO. Countries: 0. Publications: 0.
Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
ClinicalTrials.gov study NCT00645892. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
ClinicalTrials.gov study NCT01289132. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
ClinicalTrials.gov study NCT00189722. IPD Sharing: Not stated. Countries: 5. Publications: 0.
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
ClinicalTrials.gov study NCT02400866. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Effects of Therapeutic Doses of Acetaminophen in Moderate Drinkers
ClinicalTrials.gov study NCT00400621. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Effect of Changing the Activation Frequency of the Arch Wires on the Rate of Leveling and Alignment in Moderate Crowding Cases
ClinicalTrials.gov study NCT04106141. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension
ClinicalTrials.gov study NCT02177409. IPD Sharing: Not stated. Countries: 0. Publications: 0.
TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.
ClinicalTrials.gov study NCT00736905. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
ClinicalTrials.gov study NCT02170571. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.